Mink therapeutics to report first quarter 2022 financial results and business update

New york, april 27, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its first quarter 2022 financial results and business update before the market opens on tuesday, may 10, 2022.
INKT Ratings Summary
INKT Quant Ranking